Skip to main content

Table 2 Risk of malignant tumours in men up to age 99 after a histopathological verified diagnosis of gynecomastia 1970–79. Follow up time includes 1970–1999 (8375.2 years). The cohort consists of 446 men.

From: Male gynecomastia and risk for malignant tumours – a cohort study

Diagnosis   OBS EXP SIR 95% Confidence interval
140–209 All malignant tumours 68 66.07 1.03 0.80 1.30
140    Lip 1 0.70 1.43 0.04 7.97
141_3_4 Oral cavity 0 0.51 0.00 0.00 7.18
142    Parotid glands 0 0.19 0.00 0.00 19.71
145–148 Pharynx, hypopharynx 0 0.42 0.00 0.00 8.69
150    Esophagus 3 0.78 3.82 0.79 11.17
151    Stomach 3 4.09 0.73 0.15 2.15
153    Colon 7 5.43 1.29 0.52 2.66
154    Rectum 0 3.57 0.00 0.00 1.03
1550 Liver and intrahepatic ducts 1 0.94 1.06 0.03 5.90
1551–1559 Gallblader & bile ducts 1 0.67 1.50 0.04 8.34
157    Pancreas 1 1.95 0.51 0.01 2.86
160    Nasal cavities & sinus 0 0.13 0.00 0.00 27.71
161    Larynx 0 0.65 0.00 0.00 5.67
1620–1621 Trachea & lung 6 6.31 0.95 0.35 2.07
1622 Mesothelioma 0 0.31 0.00 0.00 12.04
170    Male breast cancer 0 0.09 0.00 0.00 42.96
177    Prostate 16 16.21 0.99 0.56 1.60
178    Testicle 3 0.52 5.82 1.20 17.00
180    Kidney 1 2.18 0.46 0.01 2.55
181    Urinary bl,.urinary tc. 1 4.85 0.21 0.01 1.15
190    Melanoma 0 1.73 0.00 0.00 2.1
191    Skin excl melanoma 13 4.06 3.21 1.71 5.48
193    Brain & nervous system 1 1.71 0.59 0.01 3.26
194    Thyroid 0 0.30 0.00 0.00 12.43
196–197 Bone & soft tissue 0 0.49 0.00 0.00 7.59
200+202 Non-Hodgkin's lymphoma 1 1.96 0.51 0.01 2.84
201    Hodgkin's disease 0 0.28 0.00 0.00 12.97
203    Multiple myeloma 0 0.90 0.00 0.00 4.11
Acute leukemia 1 0.54 1.86 0.05 10.38
204.1    Chr. lymph. leukemia 0 0.74 0.00 0.00 4.98
205.1    Chr myeloid leukemia 0 0.18 0.00 0.00 20.83
208    Polycythemia vera 0 0.17 0.00 0.00 21.67